Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.AGE · Entity 9581 | Chief Executive Officer | March 11, 2023 | March 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date March 11, 2023 · Filed March 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 41,982 |
Last balance in matching sequence
After 2023-03-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-03-11 · Exercise / conversion · Acquired 3,125 · Balance 43,042 F1: Excludes shares owned by former spouse of which Dr. West disclaims beneficial ownership. Row 2 · 2023-03-11 · Tax withholding · Disposed 1,060 · Balance 41,982 F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,125 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1: Excludes shares owned by former spouse of which Dr. West disclaims beneficial ownership. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2023-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-11 · Exercise / conversion · Disposed 3,125 · Balance 0 F3: Restricted Stock Units vested on March 11, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Excludes shares owned by former spouse of which Dr. West disclaims beneficial ownership.
F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,125 Restricted Stock Units, the grant of which was previously reported on a Form 4.
F3: Restricted Stock Units vested on March 11, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Lineage Cell Therapeutics, Inc.
Report date September 17, 2018 · Filed September 20, 2018
Section 16 reporting ended · disclosed 2018-09-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 893,913 |
Last balance in matching sequence
After 2018-09-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-09-17 · Exercise / conversion · Acquired 10,938 · Balance 897,696 F1: Does not include shares that may be acquired upon the exercise of certain stock options. Row 2 · 2018-09-17 · Tax withholding · Disposed 3,783 · Balance 893,913 F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 10,938 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1: Does not include shares that may be acquired upon the exercise of certain stock options. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-09-17 · Exercise / conversion · Disposed 10,938 · Balance 0 F3: Restricted Stock Units vested on September 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Does not include shares that may be acquired upon the exercise of certain stock options.
F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 10,938 Restricted Stock Units, the grant of which was previously reported on a Form 4.
F3: Restricted Stock Units vested on September 17, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 10, 2018 Filed Apr 13, 2018 01:00 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 541 | $2.49 | $1,347.09 |
DisclosureSEC source: 0001209191-18-024791 · doc4.xml · nonDerivative · entry 2 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,737 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,563 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 12,500 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| April 10, 2018 Filed Apr 13, 2018 01:00 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024791 · doc4.xml · nonDerivative · entry 1 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 12,500 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| January 10, 2018 Filed Jan 13, 2018 01:30 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003488 · doc4.xml · derivative · entry 3 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,063 Underlying: Common Shares · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on January 10, 2018. F3 · derivative.expiration_date: Restricted Stock Units vested on January 10, 2018. Read SEC document |
| January 10, 2018 Filed Jan 13, 2018 01:30 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 686 | $2.68 | $1,838.48 |
DisclosureSEC source: 0001209191-18-003488 · doc4.xml · nonDerivative · entry 2 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,715 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,562 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 14,063 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| January 10, 2018 Filed Jan 13, 2018 01:30 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003488 · doc4.xml · nonDerivative · entry 1 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 14,063 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056779 · doc4.xml · derivative · entry 3 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Shares · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on October 10, 2017. F3 · derivative.expiration_date: Restricted Stock Units vested on October 10, 2017. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 588 | $2.81 | $1,652.28 |
DisclosureSEC source: 0001209191-17-056779 · doc4.xml · nonDerivative · entry 2 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,839 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,563 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 15,625 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056779 · doc4.xml · nonDerivative · entry 1 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 15,625 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 23:23 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 2,000 | $2.60 | $5,198.00 |
DisclosureSEC source: 0001209191-17-050016 · doc4.xml · nonDerivative · entry 1 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,864 F1 · balance_after: Does not include Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 23:21 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044959 · doc4.xml · derivative · entry 3 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,188 Underlying: Common Shares · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on July 10, 2017. F3 · derivative.expiration_date: Restricted Stock Units vested on July 10, 2017. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 23:21 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 587 | $3.09 | $1,813.83 |
DisclosureSEC source: 0001209191-17-044959 · doc4.xml · nonDerivative · entry 2 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,864 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,562 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 17,188 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 23:21 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044959 · doc4.xml · nonDerivative · entry 1 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 17,188 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| April 10, 2017 Filed May 2, 2017 00:58 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029046 · doc4.xml · derivative · entry 3 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Shares · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on April 10, 2017. F3 · derivative.expiration_date: Restricted Stock Units vested on April 10, 2017. Read SEC document |
| April 10, 2017 Filed May 2, 2017 00:58 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 2,348 | $3.33 | $7,818.84 |
DisclosureSEC source: 0001209191-17-029046 · doc4.xml · nonDerivative · entry 2 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879,889 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,250 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 18,750 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| April 10, 2017 Filed May 2, 2017 00:58 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029046 · doc4.xml · nonDerivative · entry 1 WEST MICHAEL D · CIK 0001202529 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 18,750 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.